Literature DB >> 8208048

Toxicity of photodynamic therapy with photofrin in the normal rat brain.

Y Ji1, S K Powers, J T Brown, D Walstad, L Maliner.   

Abstract

The widespread acceptance of photodynamic therapy (PDT), a potential adjuvant brain tumor therapy under clinical evaluation since 1980, has been partially restrained by its potential toxicity toward normal brain tissue. This study examined PDT-produced injury of normal rat brain as a function of photosensitizer dose. Brain injury was characterized by correlating measurements of the area of cerebral edema using T2-weighted magnetic resonance images, measurement of brain water content at the lesion site, microscopic examination of histological sections through the PDT lesion, and by evaluation of the area of blood brain barrier (BBB) disruption using computerized morphometric analysis of the region of Evans blue (EB) dye-labelled albumin extravasation. Monochromatic red light (630 nm) was delivered intracerebrally using a 5-mm-long cylindrical, diffusion-tip optical fiber at a constant energy dose of 15 joules. A Photofrin dose of 2 mg/kg of body weight produced a transient breakdown in the blood brain barrier around the site of the implanted optical fiber demonstrated by magnetic resonance imaging (MRI), extravasation of EB dye and pallor on hematoxylin and eosin-stained microscopic tissue sections. A much larger area of BBB disruption was seen at a dose of 4 mg/kg of Photofrin, and this drug dose resulted in significant permanent brain injury. In this model, a Photofrin dose of 4 mg/kg body weight is not tolerated by the normal brain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8208048     DOI: 10.1002/lsm.1900140304

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  4 in total

1.  Subcutaneous Xenograft Models for Studying PDT In Vivo.

Authors:  Girgis Obaid; Tayyaba Hasan
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Physical energy for drug delivery; poration, concentration and activation.

Authors:  Shanmugamurthy Lakshmanan; Gaurav K Gupta; Pinar Avci; Rakkiyappan Chandran; Magesh Sadasivam; Ana Elisa Serafim Jorge; Michael R Hamblin
Journal:  Adv Drug Deliv Rev       Date:  2013-06-07       Impact factor: 15.470

3.  Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: a comparative study on human tumour xenografts.

Authors:  H B Ris; T Krueger; A Giger; C K Lim; J C Stewart; U Althaus; H J Altermatt
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy.

Authors:  L Lilge; M C Olivo; S W Schatz; J A MaGuire; M S Patterson; B C Wilson
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.